Trial Profile
A Phase I/II Open-Label Study of TPI 287 for Patients With Metastatic Melanoma.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 23 Dec 2013
Price :
$35
*
At a glance
- Drugs TPI 287 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 04 Apr 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 21 Mar 2013 Planned end date changed from 1 Dec 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
- 21 Mar 2013 Planned initiation date changed from 1 Dec 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.